Patient Reported Outcomes Burdens and Experiences - Phase 3
Recruiting
The PROBE Phase-3 study will collect data on patient reported outcomes, burdens, and experiences in patients living with hemophilia. The investigators will perform comparisons among countries, within country over time, within country against national normative data.
Gender:
ALL
Ages:
All
Trial Updated:
08/18/2025
Locations: McMaster University, Hamilton, Ontario
Conditions: Hemophilia, Chronic Disease
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Recruiting
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +56 locations
Conditions: Advanced Melanoma
Fibrosis Lessens After Metabolic Surgery
Recruiting
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/18/2025
Locations: Banner Health Center, Phoenix, Arizona +21 locations
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Recruiting
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Alabama at Birmingham - Main /ID# 253477, Birmingham, Alabama +64 locations
Conditions: Parkinson's Disease (PD)
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Center for Colitis and Crohns Disease University of California, San Francisco, California +72 locations
Conditions: Crohn's Disease
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Recruiting
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/18/2025
Locations: TRIHEALTH Good Samarithan Hospital, Cincinnati, Ohio +35 locations
Conditions: Follicular Lymphoma (FL)
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Recruiting
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as "study drugs" in this section. This study is looking at several other research questions, including... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Toronto General Hospital, Toronto, Ontario +35 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Recruiting
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Oruka Therapeutics Investigative Site, Fountain Valley, California +15 locations
Conditions: Plaque Psoriasis
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Recruiting
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
08/18/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +13 locations
Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Community Cancer Institute, Clovis, California +168 locations
Conditions: Myelodysplastic Syndromes
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Recruiting
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2025
Locations: University of California Irvine Medical Center, Irvine, California +66 locations
Conditions: Acute Respiratory Distress Syndrome, Infections
Effect of Music on Surgical Performance During Artificial Intelligence-Based Simulation Training
Recruiting
At the Neurosurgical Simulation and Artificial Intelligence Learning Centre, we seek to provide surgical trainees with innovative technologies that allow them to improve their surgical technical skills in risk-free environments, potentially improving patient operative outcomes. The Intelligent Continuous Expertise Monitoring System (ICEMS), a deep learning application that assesses and trains neurosurgical technical skill and provides continuous intraoperative feedback, is one such technology th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2025
Locations: Neurosurgical Simulation and Artificial Intelligence Learning Centre, Montreal, Quebec
Conditions: Surgical Education